← All reports

EBV reactivation in hospitalized COVID-19 patients cannot be conclusively linked to causation due to the study's cross-sectional design.

HealthcareScienceApr 24, 2026score 0.292 posts · 1 replies across 1 instances
The thread discusses a study on EBV reactivation in hospitalized COVID-19 patients, highlighting its cross-sectional design, small sample size, and lack of causal conclusions.

Claims

EBV reactivation in hospitalized COVID-19 patients cannot be conclusively linked to causation due to the study's cross-sectional design.
Parent: HealthcareEntity: EBV reactivationImpact: neutralDate: Apr 24, 2026Target: EBV reactivation and its relationship with COVID-19

Source posts

@[email protected]
The study is cross‑sectional: immune markers and viral DNA measured at one time point. This means no causal conclusions, EBV reactivation could be cause, consequence, or bystander. Sample size is small (61 patients), all hospitalised during the first COVID wave (no immunity). 2/7
0 boosts · 1 favs · 0 replies · Apr 24, 2026
@[email protected]
The study is cross‑sectional: immune markers and viral DNA measured at one time point. This means no causal conclusions, EBV reactivation could be cause, consequence, or bystander. Sample size is small (61 patients), all hospitalised during the first COVID wave (no immunity). 2/7
0 boosts · 0 favs · 1 replies · Apr 24, 2026